Check

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549	
wasiiiigtoii,	D.C.	20049	

Check this box if no longer subject					
to Section 16. Form 4 or Form 5					
obligations may continue. See					
Instruction 1(b).					

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Washburn Theodore James Jr.					2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS, INC. [ AGIO ]										k all app Direc	,	ng Pei	rson(s) to Is  10% O  Other (	wner
(Last) 88 SIDN	(Fi	(First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 02/20/2024								belov	below) Principal Acco		below)	·
(Street)	Street) CAMBRIDGE MA 02139				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								ine) X	<b>'</b>				
(City)	(St	ate) (2	Zip)		$ $ $ $ $ $ $ $	Check t	his box	to indi	cate that	a trans	tion Indi	ade pur	suant to a		act, instr		ten pla	an that is inte	nded to
		Table	I - No	n-Deriva	ative S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benefic	ially	<b>Own</b>	ed			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da			y/Year) Execution		ution Date,				es Acquired (A) Of (D) (Instr. 3,		4 and Securi Benef Owner		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) (D)	or Price	•		ed ction(s) 3 and 4)	(Instr. 4)		(Instr. 4)
Common	nmon stock 02/20/2			2024		S		504	D	\$26	5.63	2,741			D				
		Tal	ble II -								osed of, convertib				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution/Day/Year) if any	emed tion Date, n/Day/Year)		ransaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Dei Sed (Ins	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						

**Explanation of Responses:** 

## Remarks:

/s/ William Cook, as attorneyin-fact for Theodore James Jr. 02/22/2024 Washburn

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.